ReviewMolecular biology reports2026
Circulating lncRNA as Biomarkers and Therapeutics in Oral Cancer: Silent Scripts with Loud Impact.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Oral squamous cell carcinoma (OSCC) remains a major global health challenge due to late diagnosis, high recurrence, and limited therapeutic success. This review focuses on circulating long non-coding RNAs (lncRNAs) as emerging biomarkers and therapeutic targets that can transform the clinical management of OSCC. Unlike earlier studies restricted to tissue-based analyses, this work emphasizes circulating lncRNAs detectable in saliva, plasma, and serum, highlighting their non-invasive diagnostic potential and mechanistic relevance in tumor progression, metastasis, and therapy resistance. Relevant studies published up to 2025 were systematically reviewed from PubMed and Google Scholar to synthesize current knowledge on their biogenesis, secretion through extracellular vesicles and RNA-binding proteins, detection technologies, and clinical applicability. Several circulating lncRNAs, including HOTAIR, MALAT1, MEG3, ANRIL, and LINC00657, show strong associations with tumor stage, prognosis, and therapeutic outcomes. The review also discusses emerging RNA-based therapeutic approaches such as antisense oligonucleotides, RNA interference, and CRISPR-based gene editing. Overall, the analysis underscores the diagnostic precision, prognostic power, and therapeutic promise of circulating lncRNAs, proposing them as key components in the future of liquid biopsy-driven, personalized oncology for OSCC.
Indexed as
Identifiers
42142262What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.